Jordi Abril-Fornaguera
0000-0002-5871-4052
14 papers found
Refreshing results…
WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma
Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
Supplementary Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
Supplementary Figure from Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma
Supplementary Data from Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma
Data from Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma
Identification ofIGF2as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
PMEPA1 has an oncogenic role in hepatocellular carcinoma in the context of TGFβ signaling: data from single cell RNAseq and transgenic models
Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma
Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma
Metabolic Landscape of the Mouse Liver by Quantitative 31P Nuclear Magnetic Resonance Analysis of the Phosphorome
Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice
Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma
Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications
Missing publications? Search for publications with a matching author name.